Cervical Cancer Risk in East and Central Africa from Interaction with Falciparum Malaria
Main Article Content
Abstract
From material available from a prior case- control study conducted in Kampala, Uganda cervical cancer risks were assessed in detail for falciparum malaria alone and in combination with HPV. Single cervical cancer risks from falciparum malaria, controlled or uncontrolled for HPV, were always very low. Significant interaction was observed between falciparum malaria and HPV. When the odds ratio was used to measure interaction, in particular synergy, a significant correlation coefficient resulted for HPV and falciparum malaria among cases, but not among controls. Among HIV-negatives stepwise regression with rising level of antibodies against falciparum showed a range of risks from 5.92 up to a synergistic value of 75.15. In sequential analyses risks controlled for HPV and falciparum malaria, respectively, showed each alone for falciparum malaria an inverse estimate of 0.47 and for HPV a decreased positive value of 7.05. When falciparum malaria meets HPV or vice versa, respectively, the range between antagonistic and synergistic values remains rather large. It amounts to 2.31 - 34.94. The antagonistic interaction of falciparum malaria with HIV noted in the literature and put up as hypothesis needs further assessment. Falciparum malaria may prevent HIV-associated cervical cancer. A small significant decrease in risk observed in Rwanda could not be attributed to antiretroviral therapy in spite of almost complete coverage. As alternative may serve FM. According to official statements prevalence of malaria, formerly very low, is on the increase.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Schmauz R, Okong P, de Villiers EM, Dennin R, Brade L, Lwanga SK, Owor R. Multiple infections in cases of cervical and cancer from a high incidence area in tropical Africa. Int J Cancer 1989; 43: 805-9.
3. Odida M, Schmauz R, Lwanga SK. Grade of malignancy of cervical cancer in regions of Uganda with varying malarial endemicity. Int J Cancer 2002; 99: 737–41.
4. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study in Uganda. Infect Agent Cancer. 2011; 6(1):8
5. Odida M, Löscher T, Rehder H, Schmauz R. Malaria and cervical cancer risk from HPV in Kampala, Uganda. Epidemiol Public Health. 2024; 2(2): 1040.
6. Odida M, Rehder H, Larsen CH, Freers J, Schmauz R. Falciparum Malaria prevents HIV-associated Cervical Cancer in East and Central Africa (Hypothesis). Med Res Archives. 2025; 13( 5) (2025). DOI: https://doi.org/10.18103/mra.v13i5.6499
7. Stata: Statistical software for science. Google https://www.stata.
8. Miettinen OS. Lecture Notes, Harvard School of Public Health, 1972.
9. Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah ASV, McAllister DA, Gottlieb SL, Klug SJ, Winkler AS, Bray F, Baggaley R, Clifford GM, Broutet N, Dhalal S. Estimates of the global burden of cervical cancer associated with HIV. The Lancet Global Health, 16.11.2020 – DOI:10.1016/s2214-109X(20)30509-X.
10. Prevalence of falciparum malaria in Kampala of today (Google, accessed August, 23rd, 2025)
11. Rwanda Malaria Profile (Google, accessed July, 13th, 2024).
12. Tanzania Malaria Map (Google, accessed July, 13th, 2024).
13. MpungaT, Znaor A, Uwizeye FR, Uwase A, Munyanshongore C, Franceschi S, Clifford GM., et al. A case–control study of HIV- infection and cancer in the era of antiretroviral therapy in Rwanda. Int J Cancer 2018; 143:1348-55.
14. Kahesa C, Mwaiselage J, Wabinga HR, Ngoma T, Kalyango JN, Karamagi CA. Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening. BMC Public Health 2008; 8:262.
15. Sekirime WK, Gray R. HIV Infection among Uganda Women with Cervical Cancer: a Retrospective Study. Gynecol Obstet Invest 2007; 63:222-8.
16. Newton R, Ziegler J, Beral V, Mbidde E, Carpenter L, Wabinga H, Mbulaiteye S, Appleby P, Reeves G, Jaffe H. A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer 2001; 92: 622-7.
17. Dusingize J.C, Murenzi G, Muhoza B, Buzinge L, Remera E, Uwinkindi F, Hagenimana M, Rwibasira G, Nsanzimana S, Castle P, Anastos K, Clifford G.M. Cancer risk among people living with Human Immunodeficiency Virus (HIV) in Rwanda from 2007 to 2018. Int J Cancer 2024;12:2149.
18. Mpunga Tharcisse (Google, accessed August, 23rd, 2025).
19. Javadi K, Ferdosi-Shahandashti, Rajabnia M, Khaledi M. Vaginal microbiota and gynaecological cancers: a complex and evolving relationship. Infect Agent Cancer. 2024;19(27).
20. Engels E.A, Shiels M.S, Barnabas R.V, Bohlius J, Brennan P, Castilho J, Chanock S.J, Clarke M.A, Coghill A.E, Combes J.D, Dryden-Peterson S, D'Souza G, Gopal S, Jaquet A, Lurain K, Makinson A, Martin J, Muchengeti M, Newton R, Okuku F, Orem J, Palefsky J.M, Ramaswami R, Robbins H.A, Sigel K, Silver S, Suneja G, Yarchoan R, Clifford G.M. State of the science and future directions for research on HIV and cancer: summary of a joint workshop sponsored by IARC and NCI. Int J Cancer. 2024;154(4):596-606. DOI:10.1002/ijc.34727